Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study - The Lancet Respiratory Medicine
Progress in therapies for cystic fibrosis - The Lancet Respiratory Medicine
Frontiers | Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators | Pharmacology
Frontiers | Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators | Pharmacology
Lumacaftor | C24H18F2N2O5 - PubChem
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN) - Journal of Cystic Fibrosis
The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway | Scientific Reports
Stopcriteria CFTR-modulatoren bij CF - Richtlijn - Richtlijnendatabase
Depicting the action of Orkambi (lumacaftor + ivacaftor) and other... | Download Scientific Diagram
Lumacaftor/ivacaftor - Wikipedia
PDF) Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. - Abstract - Europe PMC
Frontiers | Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine | Pharmacology
Stopcriteria CFTR-modulatoren bij CF - Richtlijn - Richtlijnendatabase
CFTR: New insights into structure and function and implications for modulation by small molecules - Journal of Cystic Fibrosis
Frontiers | Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators | Pharmacology
Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives | Journal of Medicinal Chemistry
How ORKAMBI® (lumacaftor/ivacaftor) Works | Watch the Video
Mechanism of Action | ORKAMBI® (lumacaftor/ivacaftor)
Ivacaftor pathway, pharmacokinetics/pharmacodynamics
How ORKAMBI® (lumacaftor/ivacaftor) Works | Watch the Video
Stopcriteria CFTR-modulatoren bij CF - Richtlijn - Richtlijnendatabase
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar
